Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLee, ST-
dc.contributor.authorKulkarni, HR-
dc.contributor.authorSingh, A-
dc.contributor.authorBaum, RP-
dc.identifier.citationVisceral Medicine 2017; 33(5): 358-366en_US
dc.description.abstractSomatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.en_US
dc.subjectNeuroendocrine tumor, NETen_US
dc.subjectPeptide receptor radionuclide therapy, PRRTen_US
dc.subjectPositron emission tomography/computed tomography, PET/CTen_US
dc.titleTheranostics of Neuroendocrine Tumorsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleVisceral Medicineen_US
dc.description.affiliatesDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.description.affiliatesTHERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germanyen_US
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.

Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.